Answers are grounded in this paper and cite their sources.
These biologic endpoints establish BMTP-11 as a targeted drug candidate in metastatic, castrate-resistant prostate cancer. Within a larger discovery context, the current findings indicate that functional tumor vascular ligand-receptor targeting systems may be identified through direct combinatorial selection of peptide libraries in cancer patients.
No takes yet. Share an insight, caveat, or question.
Pasqualini et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: